Joint Shantou International Eye Center of the Shantou University & Chinese University of Hong Kong, Shantou, China.
Retina. 2011 Jun;31(6):1137-42. doi: 10.1097/IAE.0b013e3181fe5427.
To evaluate the midterm anatomical and functional outcomes of intravitreal injection of low-dose triamcinolone acetonide in silicone oil-filled eyes as an adjunctive treatment for proliferative vitreoretinopathy.
This is a retrospective interventional case series. Patients with proliferative vitreoretinopathy grade C or D received pars plana vitrectomy combined with silicone oil tamponade and intravitreal injection of 2 mg of triamcinolone acetonide in the first stage and silicone oil removal in the second stage. Primary outcome measures were retinal reattachment rate and best-corrected visual acuity.
In all, 37 eyes from 37 patients were included in this study. The mean follow-up duration was 22.9 ± 9.6 months. Retina was reattached in 36 (97.3%) eyes at the last visit. The mean best-corrected visual acuity was 1.76 ± 0.56 logMAR at baseline, which improved to 0.87 ± 0.60 logMAR at the last visit (P < 0.001). Best-corrected visual acuity increased in 31 (83.8%) eyes, remained unchanged in 5 (13.5%) eyes, and decreased in 1 (2.7%) eye at last visit compared with baseline.
Low-dose (2 mg) triamcinolone acetonide intravitreal injection as an adjunct to vitrectomy and silicone oil tamponade in treating proliferative vitreoretinopathy (grade C or D) appears to be effective and safe.
评估硅油填充眼内注射小剂量曲安奈德作为增生性玻璃体视网膜病变辅助治疗的中期解剖和功能结果。
这是一项回顾性干预性病例系列研究。增生性玻璃体视网膜病变 C 或 D 级患者接受了标准的玻璃体切除术联合硅油填充，并在第一阶段玻璃体腔内注射 2 毫克曲安奈德，在第二阶段取出硅油。主要观察指标是视网膜复位率和最佳矫正视力。
共有 37 例（37 只眼）患者纳入本研究。平均随访时间为 22.9±9.6 个月。末次随访时，36 只眼（97.3%）视网膜复位。基线时最佳矫正视力的平均 logMAR 值为 1.76±0.56，末次随访时提高至 0.87±0.60（P<0.001）。与基线相比，31 只眼（83.8%）最佳矫正视力增加，5 只眼（13.5%）保持不变，1 只眼（2.7%）下降。
对于增生性玻璃体视网膜病变（C 或 D 级），玻璃体切除联合硅油填充联合小剂量（2 毫克）曲安奈德眼内注射似乎是有效且安全的。
